Latest News

Anti-Cancer Agents & Biologic Therapy - Ovarian Cancer

Ovarian Cancer Patient QoL Preserved During Maintenance PARP Inhibitor Use

  • 19 Jul 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Long-term PARP inhibitor use does not adversely impact quality of life in patients with recurrent platinum-sensitive ovarian cancer patients compared with placebo...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Ovarian Cancer Patient QoL Preserved During Maintenance PARP Inhibitor Use

Breast Cancer, Early Stage - Surgery and/or Radiotherapy of Cancer

hsCRP Rise After Breast Cancer Radiation Predicts Severe Skin Toxicity

  • 18 Jul 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Obesity and an increase in high-sensitivity C-reactive protein are both independently linked to early skin reactions in breast cancer patients undergoing radiotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof hsCRP Rise After Breast Cancer Radiation Predicts Severe Skin Toxicity

Renal Cell Cancer - Pathology/Molecular Biology - Translational Research

Germline Mutations Prevalent In Advanced RCC Patients

  • 10 Jul 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

More than one in 10 patients with advanced renal cell carcinoma carry a germline mutation, rising to around one in five patients with non-clear cell histology...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Germline Mutations Prevalent In Advanced RCC Patients

Anti-Cancer Agents & Biologic Therapy - Renal Cell Cancer

Sorafenib–Chemotherapy Tested For Metastatic Renal Collecting Duct Carcinoma

  • 05 Jul 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

A pilot study suggests sorafenib with gemcitabine plus cisplatin may be an option for chemotherapy-naive patients with metastatic renal collecting duct carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Sorafenib–Chemotherapy Tested For Metastatic Renal Collecting Duct Carcinoma

Anti-Cancer Agents & Biologic Therapy - Anal Cancer

First-Line Modified DCF Regimen Trialled For Advanced Anal Squamous Cell Carcinoma

  • 04 Jul 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

A modified version of docetaxel, cisplatin and fluorouracil may be feasible for the treatment of metastatic or inoperable recurrent anal squamous cell carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof First-Line Modified DCF Regimen Trialled For Advanced Anal Squamous Cell Carcinoma

Anti-Cancer Agents & Biologic Therapy - Prostate Cancer - Translational Research

CTC AR-V7 Might Be Useful For Guiding Second-Line mCRPC Treatment Choices

  • 03 Jul 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Testing for AR-V7 protein in circulating tumour cells may help indicate whether taxane or androgen receptor signalling inhibitor therapy is the best option for patients with metastatic castration-resistant prostate cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof CTC AR-V7 Might Be Useful For Guiding Second-Line mCRPC Treatment Choices

Anti-Cancer Agents & Biologic Therapy - Drug Development - Breast Cancer

Dual HER2 Inhibition Tested For Metastatic Breast Cancer Patients

  • 02 Jul 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Initial findings suggest that combining tucatinib with ado-trastuzumab emtansine may have acceptable toxicity for the treatment of ERBB2/HER2-positive metastatic breast cancers...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Dual HER2 Inhibition Tested For Metastatic Breast Cancer Patients

Anti-Cancer Agents & Biologic Therapy - Colon Cancer - Rectal Cancer

Metastatic CRC Survival Boosted With Fruquintinib In Chinese Patients

  • 29 Jun 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Chinese patients whose metastatic colorectal cancer has progressed after at least two lines of chemotherapy experienced an overall survival benefit with fruquintinib...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Metastatic CRC Survival Boosted With Fruquintinib In Chinese Patients

Central Nervous System Malignancies - Translational Research

Recombinant Poliovirus May Extend Recurrent Malignant Glioma Survival

  • 28 Jun 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

A recombinant nonpathogenic polio–rhinovirus chimera may have potential for the treatment of recurrent glioma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Recombinant Poliovirus May Extend Recurrent Malignant Glioma Survival

Cancer Immunology and Immunotherapy

Overall Survival Remains ‘Gold Standard’ For PD-1 Inhibitor Trial Endpoints

  • 27 Jun 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

A meta-analysis suggests that progression-free survival may not adequately capture the benefit of PD-1 inhibitor therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Overall Survival Remains ‘Gold Standard’ For PD-1 Inhibitor Trial Endpoints

Breast Cancer - Surgery and/or Radiotherapy of Cancer

Autologous Breast Reconstruction Complications, PROs Revealed

  • 26 Jun 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Prosthetic reconstruction after mastectomy has fewer complications but patient-reported outcomes may favour autologous techniques...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Autologous Breast Reconstruction Complications, PROs Revealed

Anti-Cancer Agents & Biologic Therapy - Cancer Immunology and Immunotherapy - Head and Neck Cancers

Active8 Shows No ITT Survival Benefit For Motolimod Use In Recurrent, Metastatic SCCHN

  • 25 Jun 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Any benefit from adding the toll-like receptor 8 agonist to EXTREME treatment for advanced squamous cell carcinoma of the head and neck may be limited to select patient subgroups...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Active8 Shows No ITT Survival Benefit For Motolimod Use In Recurrent, Metastatic SCCHN

Cancer Aetiology, Epidemiology, Prevention - Familial Cancer - Pancreatic Cancer

Six Germline Mutations Linked To Pancreatic Cancer Risk

  • 22 Jun 2018

Around 5% of patients with pancreatic cancer may carry germline mutations associated with the disease...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Six Germline Mutations Linked To Pancreatic Cancer Risk

Anti-Cancer Agents & Biologic Therapy - Cancer in Special Situations

Chronic Kidney Disease Patients Increasingly Excluded From Cancer Trials

  • 21 Jun 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

The majority of trials testing drugs for breast, bladder, colorectal, lung and prostate cancer between 2012 and 2017 excluded patients on the basis of chronic kidney disease biomarkers...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Chronic Kidney Disease Patients Increasingly Excluded From Cancer Trials

ESMO E-Learning: Double-Hit Lymphomas

New E-Learning module by Georg Lenz is now available. Watch the presentation and take the CME test today!

view detailsof